Eptifibatide

The clinical translation rests on three pivotal randomised trials and one negative trial that recalibrated the position. The first pivotal readout was the IMPACT-II trial, Lancet 1997, 349:1422–1428, which randomised 4,010 patients undergoing elective, urgent, or emergency percutaneous coronary intervention across 82 US centres to placebo, to a 135 mcg/kg bolus plus 0.5 mcg/kg/min infusion of eptifibatide, or to the same bolus with a 0.75 mcg/kg/min infusion. The 30-day composite of death, myocardial infarction, unplanned revascularisation, or coronary stent implantation occurred in 11.4% of placebo patients versus 9.2% in the lower-dose eptifibatide arm (P = 0.063 by intention-to-treat, P = 0.035 by treatment-received) and 9.9% in the higher-dose arm (P = 0.22). IMPACT-II established that the GPIIb/IIIa-antagonist mechanism translated into a clinically detectable reduction in peri-PCI ischaemic events but flagged that the dose was not yet optimised and the effect size was modest at the doses tested.

The acute coronary syndrome readout came from the PURSUIT trial — the PURSUIT Investigators, N Engl J Med 1998, 339:436–443 — which randomised 10,948 patients presenting with non-ST-segment-elevation acute coronary syndromes to eptifibatide (180 mcg/kg bolus followed by 2.0 mcg/kg/min infusion for up to 72 hours, extendable to 96 hours if PCI was performed near the 72-hour mark) versus placebo, on a background of aspirin and heparin. The primary endpoint, the 30-day composite of death and nonfatal myocardial infarction, occurred in 14.2% of the eptifibatide arm versus 15.7% of placebo — an absolute reduction of 1.5 percentage points (P = 0.04). The benefit appeared early and was sustained at six-month follow-up. PURSUIT supplied the regulatory case that underwrote the May 18, 1998 FDA approval of Integrilin for acute coronary syndromes and for percutaneous coronary intervention. The effect size — small in absolute terms, statistically modest, and concentrated among patients managed with revascularisation rather than purely medically managed patients — set the tone for the class: GPIIb/IIIa antagonists worked, but they did not transform outcomes in the way that the early aggregation-pharmacology models had suggested they might.

The peri-PCI evidence base was strengthened by the ESPRIT trial — the ESPRIT Investigators, Lancet 2000, 356:2037–2044. 2,064 patients undergoing elective coronary stent implantation were randomised to placebo or to a novel double-bolus eptifibatide regimen (two 180 mcg/kg boluses 10 minutes apart, followed by a 2.0 mcg/kg/min infusion for 18 to 24 hours). The 30-day composite primary endpoint — death, myocardial infarction, urgent target-vessel revascularisation, or thrombotic bailout GPIIb/IIIa therapy within 48 hours — occurred in 10.5% of placebo patients versus 6.8% of eptifibatide patients (P = 0.0034); the trial was terminated early for efficacy. ESPRIT confirmed that the double-bolus regimen offered a substantial reduction in peri-procedural ischaemic complications during elective stent PCI when added to aspirin, heparin, and a thienopyridine background, and it underwrote the labelled PCI dosing regimen (180 mcg/kg bolus, second 180 mcg/kg bolus at 10 minutes, 2.0 mcg/kg/min infusion).

The negative readout that recalibrated routine use was the EARLY-ACS trial — Giugliano, White, Bode et al., N Engl J Med 2009, 360:2176–2190. 9,492 patients with non-ST-elevation acute coronary syndromes assigned to an invasive strategy were randomised to early routine eptifibatide (the double bolus plus standard infusion administered at least 12 hours before angiography) versus delayed provisional eptifibatide (placebo until angiography, with rescue eptifibatide reserved for thrombotic complications during PCI). The 96-hour composite primary endpoint occurred in 9.3% of the early arm versus 10.0% of the delayed arm (odds ratio 0.92, 95% CI 0.80–1.06, P = 0.23). Routine early administration produced no significant reduction in ischaemic events and was associated with significantly higher rates of bleeding and red-cell transfusion. EARLY-ACS reframed the class: GPIIb/IIIa antagonists in NSTE-ACS were not a routine background therapy but a selective tool for specific peri-procedural circumstances, and the bleeding penalty of routine use was not justified by the modest ischaemic benefit in an era of dual oral antiplatelet therapy.

The modern context is one of contraction. Two readouts in the late 2000s redefined the oral P2Y12 inhibitor benchmark and pulled clinical practice away from routine intravenous GPIIb/IIIa antagonist use. The TRITON-TIMI 38 trial, Wiviott, Braunwald, McCabe et al., N Engl J Med 2007, 357:2001–2015 established prasugrel as superior to clopidogrel in 13,608 ACS-PCI patients, at the cost of increased major bleeding; the PLATO trial, Wallentin, Becker, Budaj et al., N Engl J Med 2009, 361:1045–1057 established ticagrelor as superior to clopidogrel in 18,624 ACS patients without a significant overall bleeding penalty. Combined with EARLY-ACS, the practical consequence was that oral dual antiplatelet therapy with aspirin plus a potent P2Y12 inhibitor became the routine ACS and PCI background, and GPIIb/IIIa antagonists were repositioned as selective adjuncts for specific high-risk scenarios — bailout for no-reflow phenomena, intra-procedural thrombotic complications during stent deployment, large thrombus burden in primary PCI for STEMI, and patients in whom oral antiplatelet loading is unfeasible or has not had time to take effect. Eptifibatide remains FDA-approved on its 1998 indication and stocked in catheterisation laboratories for selective use; the routine-use posture that the PURSUIT-era guidelines reflected is gone.

The instructive parallel within the existing corpus is icatibant — another small synthetic peptide engineered around a specific endogenous-mediator-receptor pair (bradykinin and B2 in hereditary angioedema), translated from rodent pharmacology to FDA-approved on-demand acute therapeutic. The two arcs share a development category but the eptifibatide trajectory illustrates a feature of class lifecycles that the icatibant story does not: a molecule can achieve regulatory approval, become standard of care, and then have its position substantially eroded by adjacent-class progress the original programme did not anticipate. The broader framing of peptide therapeutics alongside non-peptide endogenous-mediator pharmacology is taken up in the /critic/peptides-and-hormones note. Excipient and allergen considerations for parenteral peptide products including Integrilin appear in the peptide allergens and excipients reference dossier.